In Phase C, members will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually disease progression or the members are unable to tolerate the study drugs. Achievable new ways for the analysis and treatment of AML. (A) The identification https://johnd333pak5.signalwiki.com/user